---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-117934"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:23:05.052947+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Invivyd reports preliminary Q3 2024 PEMGARDA revenue of $9.3M, withdraws 2024 guidance, targets 1H 2025 profitability

## Summary
- Preliminary Q3 2024 PEMGARDA net product revenue of $9.3M; cash and equivalents ~$107M as of Sept 30.
- Withdraws prior 2024 revenue guidance of $150-200M citing late-Q3 FDA Fact Sheet warning on pemivibart activity.
- Targets near-term profitability in 1H 2025 using existing cash, anticipated revenue growth, and operational efficiencies.
- Phase 3 CANOPY data: PEMGARDA provided 64% RRR vs placebo in months 7-12, total 12-month RRR 76% (nominal p<0.0001).
- Expects to end 2024 with $65M+ cash; no new safety signals in months 7-12 follow-up.

## SEC filing metadata
- accession: 0000950170-24-117934
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017024117934/0000950170-24-117934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017024117934/ivvd-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-117934
- JSON: https://secwatch.observer/filing/0000950170-24-117934.json
- Plain text: https://secwatch.observer/filing/0000950170-24-117934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.